Back to Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma — Clinical Trials

MONDO:0010150207 active·115 recruitingLast updated: Mar 18, 2026, 1:47 PM

Trial Landscape

Head and Neck Squamous Cell Carcinoma has one of the most active rare disease trial programs, driven by drug treatment and procedure.

115

Recruiting

207

Active Trials

By Approach

Drug Treatment254

Procedure101

Biological Therapy73

Medical Device4

72 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

122

Phase 2

183

Phase 3

Phase 4

63 trials are observational or have no phase designation.

Sponsor Types

Academic/Other222Industry114NIH16Collaborative Network2

Top Sponsors

A2 Biotherapeutics Inc.

ALX Oncology Inc.

AVEO Pharmaceuticals, Inc.

AbbVie

AgonOx, Inc.

Akeso

Trial Locations

United States178 trials

China82 trials

France37 trials

Spain34 trials

United Kingdom28 trials

South Korea24 trials

Australia23 trials

Germany21 trials

Canada20 trials

Taiwan19 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

354 Trials

Phase 3Recruiting

NCT06589804

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2025Est. completion: Nov 2029Updated: Mar 2026

Phase 3Recruiting

NCT06129864

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Sponsor:AstraZeneca

United StatesStarted: Dec 2023Est. completion: Sep 2030Updated: Mar 2026

Phase 3Recruiting

NCT05815927

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Sponsor:European Organisation for Research and Treatment of Cancer - EORTC

BelgiumStarted: May 2025Est. completion: Mar 2030Updated: Feb 2026

Phase 3Recruiting

NCT04966481

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Sponsor:Washington University School of Medicine

United StatesStarted: Apr 2022Est. completion: Feb 2028Updated: Aug 2025

Phase 3Recruiting

NCT06492460

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Sponsor:Sun Yat-sen University

ChinaStarted: Sep 2024Est. completion: Jul 2033Updated: Aug 2025

Phase 3Recruiting

NCT06248996

a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients

Sponsor:Lund University Hospital

SwedenStarted: Mar 2024Est. completion: Mar 2033Updated: Sep 2024

Last updated over 18 months ago

Phase 3Recruiting

NCT05044117

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Sponsor:Sun Yat-sen University

ChinaStarted: Oct 2021Est. completion: Oct 2026Updated: Mar 2022

Last updated over 18 months ago

Phase 2Recruiting

NCT07195734

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Oct 2026Est. completion: Feb 2033Updated: Mar 2026

Phase 2Recruiting

NCT04671667

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Apr 2021Est. completion: Jun 2029Updated: Mar 2026

Phase 2Recruiting

NCT06980038

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2026Est. completion: Nov 2027Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT05721755

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor:ECOG-ACRIN Cancer Research Group

United StatesStarted: Jun 2023Est. completion: Mar 2030Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT07435324

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Sponsor:R-Pharm

RussiaStarted: Aug 2024Est. completion: Jun 2026Updated: Feb 2026

Phase 3Active, Not Recruiting

NCT03340896

Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Sponsor:Groupe Oncologie Radiotherapie Tete et Cou

FranceStarted: Jun 2015Est. completion: Nov 2028Updated: Sep 2025

Phase 3Active, Not Recruiting

NCT02998385

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

Sponsor:Groupe Oncologie Radiotherapie Tete et Cou

FranceStarted: Jan 2017Est. completion: Mar 2030Updated: May 2025

Phase 3Active, Not Recruiting

NCT02999087

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

Sponsor:Groupe Oncologie Radiotherapie Tete et Cou

FranceStarted: Sep 2017Est. completion: Dec 2027Updated: May 2025

Phase 2Active, Not Recruiting

NCT05172258

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2022Est. completion: Jun 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT05063552

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2023Est. completion: Dec 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02769520

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Sponsor:Assuntina G. Sacco, MD

United StatesStarted: Jul 2016Est. completion: Apr 2026Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT03468218

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Sponsor:Emory University

United StatesStarted: Sep 2018Est. completion: Oct 2026Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT03546582

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Sponsor:RTOG Foundation, Inc.

United StatesStarted: Nov 2018Est. completion: Jul 2029Updated: Jan 2026

Stay informed about clinical trials for Head and Neck Squamous Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 18, 2026 at 1:47 PM

Head and Neck Squamous Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

354 Trials

Open Trials148

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Active Trials59

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Other147